stockrowArcutis Biotherapeutics, Inc. (ARQT) vs Definium Therapeutics, Inc. (DFTX)
- Arcutis Biotherapeutics, Inc. ARQT 25.55 −5.37%
- Definium Therapeutics, Inc. DFTX 33.27 +9.58%
Arcutis Biotherapeutics, Inc. and Definium Therapeutics, Inc. are both Biotechnology companies. Definium Therapeutics, Inc. is the larger, with a market value of $4.1B against $3.4B — 1.2× the size. Definium Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; Arcutis Biotherapeutics, Inc. trades at 119×. Arcutis Biotherapeutics, Inc. has the higher net margin (5.88% vs 0.00%) and the higher return on invested capital (23.5% vs 0.00%). Across the 14 metrics below, Arcutis Biotherapeutics, Inc. leads on 10 and Definium Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | ARQT | DFTX | Biotechnology median |
|---|---|---|---|
| Gross margin | 91.18% | 0.00% | 65.16% |
| Operating margin | 6.91% | 0.00% | 0.00% |
| Net margin | 5.88% | 0.00% | 0.00% |
| Free cash flow margin | 11.74% | 0.00% | 0.00% |
| Return on equity | 14.88% | (64.09%) | (50.12%) |
| Return on assets | 6.68% | (51.35%) | (45.60%) |
| Return on invested capital | 23.48% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack